Olema Oncology

Olema Oncology

Founded 2007

San Francisco, United States 164 employees Post-IPO Equity Total: $325.05M Biopharma, Biotechnology +2

Olema Oncology is a biopharmaceutical company that focuses on developing innovative targeted therapies for women's cancers. Their lead program, OP-1250, is a potential best-in-class complete estrogen receptor antagonist (CERAN) designed to treat estrogen receptor-positive (ER+), human epidermal growth factor receptor 2-negative (HER2-) breast cancer. Recently, they initiated a Phase 1/2 dose-escalation and expansion clinical trial of OP-1250. The company was founded in 2007 and is headquartered in the United States. Supported by a team of experienced and accomplished scientists and board members, leading healthcare investors, and innovative pharma companies, Olema is strategically positioned to make significant advancements in the field of cancer treatment. Their commitment to innovation and strong backing from healthcare investors is demonstrated through their latest $130.00M Post-IPO Equity investment at 13 September 2023. Olema's dedication to developing novel therapies for women's cancers, along with their successful fundraising efforts, positions them as a promising player in the biopharma, biotechnology, healthcare, and pharmaceutical industries. For more information, visit their website at www.olema.com. (Note: Olema does not conduct interviews via text message or messaging platforms and does not ask candidates to download anything as part of the interview process. They utilize third-party tools for job advertisements, urging candidates to verify the communication's authenticity.)

Funding Stage	Amount	Investors	Lead Investors	Date
Post IPO Debt	$50.00M	1	Silicon Valley Bank	05 Sep 2023
Post IPO Equity	$130.00M	8	Lightspeed Venture Partners, Vivo Capital +6	05 Sep 2023
Series C	$85.00M	10	RA Capital Management, Venrock +8	01 Oct 2020
Series B	$54.00M	9	RA Capital Management, Venrock +7	22 Jul 2020
Series A	$6.05M	1	Biotechnology Value Fund	23 Aug 2018

Funding Stage

Amount

Investors

Lead Investors

Date

Post IPO Debt

$50.00M

Silicon Valley Bank

05 Sep 2023

Post IPO Equity

$130.00M

Lightspeed Venture Partners, Vivo Capital +6

05 Sep 2023

Series C

$85.00M

RA Capital Management, Venrock +8

01 Oct 2020

Series B

$54.00M

RA Capital Management, Venrock +7

22 Jul 2020

Series A

$6.05M

Biotechnology Value Fund

23 Aug 2018

FAQ About Olema Oncology

Olema Oncology was founded in 2007.

Olema Oncology is headquartered in San Francisco, United States.

Olema Oncology operates in Biopharma, Biotechnology, Health Care and Pharmaceutical. Its work centres on biopharmaceutical company, targeted therapies, women's cancers and OP-1250.

Olema Oncology has approximately 164 employees.

Olema Oncology has completed 5 funding rounds, raising a total of $325.05M. The latest funding stage is Post-IPO Equity.

Top alternatives and competitors to Olema Oncology include Sermonix Pharmaceuticals, Oncolix, ORIC Pharmaceuticals Inc., Repare Therapeutics, Apollomics. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.

Olema Oncology and Sermonix Pharmaceuticals are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

General Information

Discover More

About Olema Oncology

Funding Rounds & Investors (5)

Olema Oncology Alternatives & Competitors

FAQ About Olema Oncology